Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Total Non-Current Liabilities data on file, last reported at $123.0 million in Q4 2023.

• On a quarterly basis, Total Non-Current Liabilities fell 70.54% year-over-year to $123.0 million in Q4 2023; TTM through Dec 2023 was $123.0 million, a 70.54% decrease from a year earlier, with the FY2023 full-year figure at $123.0 million, down 70.54% from the prior year.
• Total Non-Current Liabilities for Q4 2023 stood at $123.0 million, up from $118.1 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for DNLI reached as high as $453.0 million in Q4 2020 and fell as low as $118.1 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $289.1 million across 5 years, with a median of $295.0 million in 2020.
• Across the five-year window, Total Non-Current Liabilities surged 201.41% in 2021 and tumbled 71.61% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $158.0 million in 2019, then jumped by 186.81% to $453.0 million in 2020, then decreased by 2.55% to $441.5 million in 2021, then dropped by 5.45% to $417.4 million in 2022, then sank by 70.54% to $123.0 million in 2023.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $123.0 million in Q4 2023, $118.1 million in Q3 2023, and $118.5 million in Q2 2023.